Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Profession Glaucoma, Health Economics and Policy, Business and Innovation

Ring in the Changes

In patients with glaucoma, every missed dose of topical antiglaucoma therapy means poorer IOL control and faster vision loss. Regimen adherence varies from patient to patient, and missing a dose now and then isn’t the end of the world. But IOP control often requires multiple drops, and the effect of missing doses can quickly add up. Naturally, anything that can support medication compliance will help patients preserve their vision for longer.

One approach that’s currently being investigated is a drug-eluting ocular insert ring (ForSight VISION5), which is placed on the upper and lower fornices of patients’ eyes (Figure 1). Comprised of a 1 mm bimatoprost-silicone matrix, the ring elutes therapeutic drug doses over a 6-month period. Results of a Phase II trial comparing the bimatoprost ring plus artificial tears with a placebo ring plus twice daily timolol 0.5% eyedrops in patients (n=130) with open-angle glaucoma or ocular hypertension controllable by monotherapy are now published (1). In this multicenter, randomized, double-masked trial, the primary efficacy measure was the difference in mean (diurnal) IOP change from baseline.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Related Event

-

Cataract Surgery: Telling It Like It Is 2020

Orlando, Florida, USA

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register